ASCO 2024: eNSCLC

Test More of Your Knowledge of eNSCLC From ASCO 2024!

Do you remember the eNSCLC research presented at ASCO 2024? Test more of your knowledge with new questions and see how you rank!

Aug 20, 2024

Do you remember the eNSCLC research presented at ASCO 2024? Test your knowledge now and see how you rank!

Aug 16, 2024

A curated eBook featuring ASCO 2024 eNSCLC-focused studies, findings, and expert opinions.

Aug 7, 2024

Biomarker tests for non-small lung cancer (NSCLC) improve patient outcomes, but they are not available to everyone.

Jul 25, 2024

An increasing number of patients with eNSCLC currently have access to biomarker testing and targeted therapies, according to the MYLUNG consortium.

Jul 15, 2024

PW QUIZ

AI detects lung cancer better than humans do.

Jun 28, 2024

Ultrasensitive Circulating Tumor DNA improves clinical sensitivity of minimal residual disease in early stage non-small cell lung cancer.

Jun 13, 2024

The treatment landscape for non-small cell lung cancer has significantly evolved with the advent of targeted therapies.

May 28, 2024

The following is a summary of “J-TAIL-2: A prospective observational study of atezolizumab...

May 28, 2024